Impact of Preanalytical and Analytical Methods on Cell-Free DNA Diagnostics

被引:17
|
作者
Krasic, Jure [1 ,2 ,3 ]
Abramovic, Irena [1 ,2 ,3 ]
Vrtaric, Alen [3 ,4 ]
Gabaj, Nora Nikolac [3 ,4 ,5 ]
Kralik-Oguic, Sasa [3 ,6 ]
Bojanac, Ana Katusic [1 ,3 ]
Jezek, Davor [3 ,7 ]
Sincic, Nino [1 ,2 ,3 ]
机构
[1] Univ Zagreb, Sch Med, Dept Med Biol, Zagreb, Croatia
[2] Univ Zagreb, Sch Med, Sci Grp Res Epigenet Biomarkers, Zagreb, Croatia
[3] Univ Zagreb, Ctr Excellence Reprod & Regenerat Med, Sch Med, Zagreb, Croatia
[4] Sestre Milosrdnice Univ Hosp Ctr, Dept Clin Chem, Zagreb, Croatia
[5] Univ Zagreb, Fac Pharm & Biochem, Zagreb, Croatia
[6] Univ Hosp Ctr Zagreb, Clin Inst Lab Diagnost, Zagreb, Croatia
[7] Univ Zagreb, Sch Med, Dept Histol & Embryol, Zagreb, Croatia
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2021年 / 9卷
关键词
cell-free DNA; liquid biopsy; blood plasma; seminal plasma; preanalytics; cell-free DNA methylation; cell-free DNA integrity; CIRCULATING TUMOR DNA; SEMINAL PLASMA; EXTRACTION METHOD; QUALITY; BLOOD; HYPOMETHYLATION; METHYLATION; QUANTITY; MUTATION;
D O I
10.3389/fcell.2021.686149
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
While tissue biopsy has for the longest time been the gold-standard in biomedicine, precision/personalized medicine is making the shift toward liquid biopsies. Cell-free DNA (cfDNA) based genetic and epigenetic biomarkers reflect the molecular status of its tissue-of-origin allowing for early and non-invasive diagnostics of different pathologies. However, selection of preanalytical procedures (including cfDNA isolation) as well as analytical methods are known to impact the downstream results. Calls for greater standardization are made continuously, yet comprehensive assessments of the impact on diagnostic parameters are lacking. This study aims to evaluate the preanalytic and analytic factors that influence cfDNA diagnostic parameters in blood and semen. Text mining analysis has been performed to assess cfDNA research trends, and identify studies on isolation methods, preanalytical and analytical impact. Seminal and blood plasma were tested as liquid biopsy sources. Traditional methods of cfDNA isolation, commercial kits (CKs), and an in-house developed protocol were tested, as well as the impact of dithiothreitol (DTT) on cfDNA isolation performance. Fluorimetry, qPCR, digital droplet PCR (ddPCR), and bioanalyzer were compared as cfDNA quantification methods. Fragment analysis was performed by qPCR and bioanalyzer while the downstream application (cfDNA methylation) was analyzed by pyrosequencing. In contrast to blood, semen as a liquid biopsy source has only recently begun to be reported as a liquid biopsy source, with almost half of all publications on it being review articles. Experimental data revealed that cfDNA isolation protocols give a wide range of cfDNA yields, both from blood and seminal plasma. The addition of DTT to CKs has improved yields in seminal plasma and had a neutral/negative impact in blood plasma. Capillary electrophoresis and fluorometry reported much higher yields than PCR methods. While cfDNA yield and integrity were highly impacted, cfDNA methylation was not affected by isolation methodology or DTT. In conclusion, NucleoSnap was recognized as the kit with the best overall performance. DTT improved CK yields in seminal plasma. The in-house developed protocol has shown near-kit isolation performance. ddPCR LINE-1 assay for absolute detection of minute amounts of cfDNA was established and allowed for quantification of samples inhibited in qPCR. cfDNA methylation was recognized as a stable biomarker unimpacted by cfDNA isolation method. Finally, semen was found to be an abundant source of cfDNA offering potential research opportunities and benefits for cfDNA based biomarkers development related to male reproductive health.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Cell-free DNA in cancer: current insights
    Fettke, Heidi
    Kwan, Edmond M.
    Azad, Arun A.
    CELLULAR ONCOLOGY, 2019, 42 (01) : 13 - 28
  • [22] Cell-Free DNA Fragmentomics in Liquid Biopsy
    Ding, Spencer C.
    Lo, Y. M. Dennis
    DIAGNOSTICS, 2022, 12 (04)
  • [23] Role of cell-free DNA in haematological malignancies
    Lim, Jun K.
    Kuss, Bryone
    Talaulikar, Dipti
    PATHOLOGY, 2021, 53 (03) : 416 - 426
  • [24] Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer
    Chen, Qian
    Zhang, Zi-Han
    Wang, Shu
    Lang, Jing-He
    ONCOTARGETS AND THERAPY, 2019, 12 : 11517 - 11530
  • [25] Cell-free circulating tumor DNA in cancer
    Qin, Zhen
    Ljubimov, Vladimir A.
    Zhou, Cuiqi
    Tong, Yunguang
    Liang, Jimin
    CHINESE JOURNAL OF CANCER, 2016, 35
  • [26] Size distribution of cell-free DNA in oncology
    Udomruk, Sasimol
    Orrapin, Santhasiri
    Pruksakorn, Dumnoensun
    Chaiyawat, Parunya
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 166
  • [27] Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer
    Gianni, Caterina
    Palleschi, Michela
    Merloni, Filippo
    Di Menna, Giandomenico
    Sirico, Marianna
    Sarti, Samanta
    Virga, Alessandra
    Ulivi, Paola
    Cecconetto, Lorenzo
    Mariotti, Marita
    De Giorgi, Ugo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [28] Cell-free DNA and the monitoring of lymphoma treatment
    Camus, Vincent
    Jardin, Fabrice
    PHARMACOGENOMICS, 2019, 20 (18) : 1271 - 1282
  • [29] Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook
    Ng, Charlotte K. Y.
    Di Costanzo, Giovan Giuseppe
    Terracciano, Luigi M.
    Piscuoglio, Salvatore
    FRONTIERS IN MEDICINE, 2018, 5
  • [30] Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?
    Jeepalyam, Sravan
    Sheel, Ankur
    Ejaz, Aslam
    Miller, Eric
    Manne, Ashish
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)